Trial · NCT00642369
A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia
NCT00642369, Not applicable, Completed, Guang Dong Provincial Mental Health Institute; results first posted 2014-04-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia. Trials, record NCT00642369. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00642369
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia
- NCT number
- NCT00642369
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 60 participants, actual
- Lead sponsor
- Guang Dong Provincial Mental Health Institute
- Conditions
- Schizophrenia
- Interventions
- quetiapine fumarate, haloperidol
- First posted
- 2008-03-25
- Last updated
- 2014-04-17
- Results first posted
- 2014-04-17
- Limitations and caveats
- the present study lasted for only 4 weeks. it might be too short to investigate the effect of quetiapine fumarate and haloperidol on sleep and clinical parameters.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Slow Wave Sleep | 28 days | The primary variable is the change of percentage of slow wave sleep (SWS) from baseline to the 28th day (LOCF). |
| Primary | Percentage of Rapid Eye Movement Sleep | 28 days | The primary variable is the change of the percentage of rapid eye movement (REM)sleep from baseline to the 28th day (LOCF). |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Slow Wave Sleep | 28 days | percentage of slow wave sleep | MEAN | |
| PRIMARY | Percentage of Rapid Eye Movement Sleep | 28 days | For the need of the statistical analysis, the study group and the control group are 30 evaluable patients respectively. Finally, in consideration of 25% un-evaluable patients after randomisation, there should be 80 patients randomised in this study with 40 patients per arm. | percentage of rapid eye movement sleep | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Slow Wave Sleep | Quetiapine Fumarate | percentage at baseline | 10.5 | Standard Deviation 5.5 | percentage of slow wave sleep |
| Percentage of Slow Wave Sleep | Haloperidol | percentage at baseline | 8.6 | Standard Deviation 7.6 | percentage of slow wave sleep |
| Percentage of Slow Wave Sleep | Quetiapine Fumarate | percentage on the 28th day | 9.2 | Standard Deviation 8.0 | percentage of slow wave sleep |
| Percentage of Slow Wave Sleep | Haloperidol | percentage on the 28th day | 6.3 | Standard Deviation 5.4 | percentage of slow wave sleep |
| Percentage of Slow Wave Sleep | Quetiapine Fumarate | percentage change from baseline to the 28th day | -1.4 | Standard Deviation 1.1 | percentage of slow wave sleep |
| Percentage of Slow Wave Sleep | Haloperidol | percentage change from baseline to the 28th day | -2.3 | Standard Deviation 1.8 | percentage of slow wave sleep |
| Percentage of Rapid Eye Movement Sleep | Quetiapine Fumarate | percentage at baseline | 12.6 | Standard Deviation 9.1 | percentage of rapid eye movement sleep |
| Percentage of Rapid Eye Movement Sleep | Haloperidol | percentage at baseline | 13.2 | Standard Deviation 5.3 | percentage of rapid eye movement sleep |
| Percentage of Rapid Eye Movement Sleep | Quetiapine Fumarate | percentage on the 28th day | 16.4 | Standard Deviation 9.2 | percentage of rapid eye movement sleep |
| Percentage of Rapid Eye Movement Sleep | Haloperidol | percentage on the 28th day | 10.4 | Standard Deviation 11.3 | percentage of rapid eye movement sleep |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Quetiapine Fumarate | 30 | |
| Overall Study | STARTED | Haloperidol | 30 | |
| Overall Study | COMPLETED | Quetiapine Fumarate | 25 | |
| Overall Study | COMPLETED | Haloperidol | 24 | |
| Overall Study | NOT COMPLETED | Quetiapine Fumarate | 5 | |
| Overall Study | NOT COMPLETED | Haloperidol | 6 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Quetiapine Fumarate | ||
| Total, all-cause mortality | Haloperidol | ||
| Total, other adverse events | Quetiapine Fumarate | 0 | 30 |
| Total, other adverse events | Haloperidol | 0 | 30 |
| Total, serious adverse events | Quetiapine Fumarate | 0 | 30 |
| Total, serious adverse events | Haloperidol | 0 | 30 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Quetiapine Fumarate vs Haloperidol: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00642369
GET https://conductscience.org/api/trials/v1/NCT00642369/registered